Skip to content

The Influences of Dialysate Bicarbonate Concentrations on Hemodialysis Patients

The Influences of Dialysate Bicarbonate Concentrations on Hemodialysis Patients

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04070690
Enrollment
60
Registered
2019-08-28
Start date
2019-08-31
Completion date
2020-02-29
Last updated
2019-08-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

End Stage Renal Disease on Dialysis

Keywords

metabolic acidosis, sodium bicarbonate, hemodialysis, dialysate

Brief summary

Background: Patients with decreased kidney function are in the positive acid balance due to insufficient renal acid excretion. To correct the varying degrees of metabolic acidosis in these HD patients, a high concentration of HCO3 in the dialysate is routinely used. During every 3-to-4 hours of HD treatment, a massive surge of HCO3 would enter the circulation and typically overcorrects predialysis acidosis to alkalosis and alkalemia. The sharp acid-base shift can cause some adverse consequences. The investigators believe that the rapid correction (or overcorrection) from the pre-dialysis metabolic acidosis to post-dialysis metabolic alkalosis during the 3-to-4 hours HD treatment would relate to adverse effects on HD patients. Thus the investigators conduct this study to prove the hypothesis that prevention of post-dialysis alkalosis by using lower dialysate HCO3 concentration might cause less adverse outcomes in ESRD patients on HD. Study design: Prospective cross-over case-control study. Study population: A total of 60 patients who receive regular hemodialysis (three times per week) for more than 6 months in the regional teaching hospital.

Interventions

PROCEDUREConcentration of dialysate bicarbonate

Adjust the dialysate bicarbonate concentration

Sponsors

Camillians Saint Mary's Hospital Luodong
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 99 Years
Healthy volunteers
No

Inclusion criteria

* adult uremic patients who received hemodialysis thrice weekly

Exclusion criteria

* Hospitalized patients * Patients newly initiated on HD (\<6 months) * Patients with HD access problems * Patients recently discharged from the hospital (within one month). * Patients on chemotherapy for cancer. * Patients with a kidney transplant. * Patients on steroids or other immunosuppressive therapy. * Patients with recent surgery (within one month) * Patients with an active bacterial infection. * Patients with decompensated cirrhosis.

Design outcomes

Primary

MeasureTime frameDescription
Blood pressure during the hemodialysisfour monthsBlood pressure will be measured every 1 hour during the hemodialysis
Respiratory rate during the hemodialysisfour monthsRespiratory rate will be measured every 1 hour during the hemodialysis
O2 saturation during the hemodialysisfour monthsO2 saturation will be measured every 1 hour during the hemodialysis

Countries

Taiwan

Contacts

Primary ContactChih-Chung Shiao, MD
chungyy2001@yahoo.com.tw+88639544106

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026